Who Owns Ozempic?
Updated onExplore the ownership hierarchy of Ozempic. See parent companies, holding structures, and ultimate controllers.
Ownership Chain
Ozempic
Ozempic is a once-weekly semaglutide injection brand for adults with type 2 diabetes to improve blood sugar control and reduce risks of major cardiovascular and kidney events, marketed by Novo Nordisk.
Novo Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company that researches, manufactures, and markets treatments for diabetes, obesity, rare diseases, and other chronic conditions.
Novo Holdings
Novo Holdings is a privately held holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis and investing globally with a focus on life sciences and long-term returns.
Novo Nordisk Foundation
Novo Nordisk Foundation is an independent Danish enterprise foundation that uses returns from its ownership and investments to fund scientific, humanitarian and social initiatives in health, sustainability and the life sciences.
Ozempic
Ozempic is a once-weekly semaglutide injection brand for adults with type 2 diabetes to improve blood sugar control and reduce risks of major cardiovascular and kidney events, marketed by Novo Nordisk.
Novo Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company that researches, manufactures, and markets treatments for diabetes, obesity, rare diseases, and other chronic conditions.
Novo Holdings
Novo Holdings is a privately held holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis and investing globally with a focus on life sciences and long-term returns.
Novo Nordisk Foundation
Novo Nordisk Foundation is an independent Danish enterprise foundation that uses returns from its ownership and investments to fund scientific, humanitarian and social initiatives in health, sustainability and the life sciences.
Major Shareholders
Novo Nordisk
Major Shareholders
| Name | Type | Ownership | Voting | As of |
|---|---|---|---|---|
Novo Holdings A/S Controlling shareholder of Novo Nordisk A/S. Holds all unlisted A-shares and a portion of B-shares, corresponding to about 28.1% of total share capital and ~77.1% of voting rights as of end-2024. Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation (an enterprise foundation), which thereby indirectly controls the same stake. | Corporate | 28.1% | 77.1% | Dec 2024 |
Novo Holdings
Major Shareholders
| Name | Type | Ownership | Voting | As of |
|---|---|---|---|---|
Novo Nordisk Foundation Sole shareholder of Novo Holdings A/S; the Foundation describes Novo Holdings as its fully owned subsidiary and its articles of association state that the Foundation is the sole shareholder of Novo Holdings A/S. | Institutional | 100.0% | 100.0% | Dec 2024 |
Get Started
Your ultimate competitive playbook
You just found your top competitors. Now let's map your whole landscape and show you how to stand out.
Competitive Landscape Report
Built for small teams who can't hire a full-time analyst.
$129 $260 one-time payment
Generated in minutes, no subscription.
Instead of guessing what to do about your competitors, get a done-for-you intelligence report
Competitor Map
Direct, indirect, and alternative competitors mapped across your market
Positioning Analysis
How each competitor positions, their ICP, and key differentiators
Feature & Pricing Matrix
Side-by-side comparison of features, pricing, and packaging strategies
Growth Channel Analysis
SEO, paid ads, content, and social strategies across the landscape
Reputation & Social Proof
Ratings, reviews, and sentiment analysis across all competitors
90-Day Action Plan
Specific tactics to differentiate and win more deals in the next 3 months